In a recent study from the University of Hong Kong, a cutting-edge medication for managing type 2 diabetes, known as sodium-glucose cotransporter 2 inhibitors (SGLT2i), has been shown to potentially reduce the risk of kidney and lung diseases.
The diseases in question include end-stage renal disease (ESRD), obstructive airway disease (OAD), and pneumonia.
The Superiority of SGLT2i over Older Diabetes Drugs
The study provided valuable, real-world evidence that this innovative diabetes drug might be superior to an older class of glucose-lowering drugs, known as dipeptidyl peptidase-4 inhibitors (DPP4i), in safeguarding people with type 2 diabetes.
SGLT2i represents a new generation of second-line glucose-lowering medications intended for managing type 2 diabetes.
In addition to controlling blood sugar levels, recent studies have demonstrated that SGLT2i also provides cardiac and kidney protection for patients with type 2 diabetes.
However, the question of whether SGLT2i could provide enhanced cardiorenal protection compared to individual classes of older glucose-lowering drugs, such as DPP4i, which have been widely prescribed in recent years, remained unclear.
Investigating the Association of SGLT2i with Kidney and Lung Health
In this study, the research team sought to explore the relationship between SGLT2i and the health of the kidneys and lungs.
They examined data from over 30,000 patients with type 2 diabetes in Hong Kong.
Their findings revealed that compared to DPP4i, SGLT2i was strongly associated with a lower risk of various kidney diseases.
This aligns with previous research results and provides real-world evidence suggesting that SGLT2i could offer additional kidney protective effects.
Moreover, the team also discovered that SGLT2i were strongly linked to significantly reduced risks of several lung diseases.
This led them to recommend that clinical trials should be conducted to examine these respiratory outcomes further.
Concluding Remarks: The Potential of SGLT2i
In conclusion, SGLT2i could potentially serve as a better alternative medication to DPP4i for people with type 2 diabetes.
This drug does not only aid in managing blood glucose levels but also shows promising potential in reducing the risk of renal and respiratory diseases, thus improving the overall quality of life for patients with type 2 diabetes.
If you care about diabetes, please read studies that pomace olive oil could help lower blood cholesterol, and honey could help control blood sugar.
For more information about health, please see recent studies that blueberries strongly benefit people with metabolic syndrome, and results showing widely used diabetes drug metformin may reduce cognitive decline.
The study was conducted by Dr. Cheung Ching-lung et al and published in The Journal of Clinical Endocrinology & Metabolism and JAMA Network Open.
Copyright © 2023 Knowridge Science Report. All rights reserved.